Abstract
Epilepsy is one of the commonly occurring chronic neurological disorders which involves abnormal electrical impulses in the brain. It is characterized by the sudden loss of consciousness, followed by abnormal shaking of the body. Though there are various types of antiepileptic drugs available clinically, the treatment of epilepsy still remains inadequate because of their toxicity and idiosyncratic side effects. Thus, there is unmet medical need to develop safe drugs for the treatment of epilepsy with lower side effects and improved bioavailability profiles. Considering the structural similarity between phenytoin/lamotrigine, a series of 1,3,4-thiadiazole was designed based on molecular docking study into the active site of the voltage-gated sodium channels. Antiepileptic activity of the synthesized compounds was evaluated in rats by maximal electroshock induced seizures (MES) model at different doses. Among the tested compounds, some exhibited significant anticonvulsant activity as compared to phenytoin in a dose-dependent manner. The neurotoxicity study was carried out using the rotarod test and the results of which suggests that the target compounds are safe and could be further developed as potential lead for antiepileptic drugs.
Keywords: Antiepileptic activity, docking study, epilepsy, green synthesis, neurotoxicity, thiadiazole.
Mini-Reviews in Medicinal Chemistry
Title:Molecular Docking Study, Green Synthesis and Pharmacological Evaluation of 1,3,4-thiadiazole Derivatives as Potential Antiepileptic Agents
Volume: 13 Issue: 14
Author(s): Biswa Mohan Sahoo, S. C. Dinda, B. V.V. Ravi Kumar, J. R. Panda and Pathik S. Brahmkshatriya
Affiliation:
Keywords: Antiepileptic activity, docking study, epilepsy, green synthesis, neurotoxicity, thiadiazole.
Abstract: Epilepsy is one of the commonly occurring chronic neurological disorders which involves abnormal electrical impulses in the brain. It is characterized by the sudden loss of consciousness, followed by abnormal shaking of the body. Though there are various types of antiepileptic drugs available clinically, the treatment of epilepsy still remains inadequate because of their toxicity and idiosyncratic side effects. Thus, there is unmet medical need to develop safe drugs for the treatment of epilepsy with lower side effects and improved bioavailability profiles. Considering the structural similarity between phenytoin/lamotrigine, a series of 1,3,4-thiadiazole was designed based on molecular docking study into the active site of the voltage-gated sodium channels. Antiepileptic activity of the synthesized compounds was evaluated in rats by maximal electroshock induced seizures (MES) model at different doses. Among the tested compounds, some exhibited significant anticonvulsant activity as compared to phenytoin in a dose-dependent manner. The neurotoxicity study was carried out using the rotarod test and the results of which suggests that the target compounds are safe and could be further developed as potential lead for antiepileptic drugs.
Export Options
About this article
Cite this article as:
Sahoo Mohan Biswa, Dinda C. S., Kumar V.V. Ravi B., Panda R. J. and Brahmkshatriya S. Pathik, Molecular Docking Study, Green Synthesis and Pharmacological Evaluation of 1,3,4-thiadiazole Derivatives as Potential Antiepileptic Agents, Mini-Reviews in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/13895575113136660099
DOI https://dx.doi.org/10.2174/13895575113136660099 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Relationship Between Epilepsy and Depression: An Update
Current Medicinal Chemistry Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry Neurophysiological Alterations in the Prepsychotic Phases
Current Pharmaceutical Design ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry Microglial Proteases: Strategic Targets for Neuroprotective Agents
Current Neuropharmacology <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook
Current Drug Delivery Recent Patents and Discovery of Anti-inflammatory Agents from Marine Source
Recent Patents on Inflammation & Allergy Drug Discovery The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography
Current Pharmaceutical Design Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Subject Index To Volume 12
Current Pharmaceutical Design The Effects of Hydroalcoholic Extract of Pinus eldarica on Hippocampal Tissue Oxidative Damage in Pentylenetetrazole-Induced Seizures in Rat
Current Nutrition & Food Science Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism